SION
NASDAQ · Biotechnology
Sionna Therapeutics Inc
$36.39
+0.90 (+2.54%)
Financial Highlights (FY 2025)
Revenue
242.99M
Net Income
-48,406,908
Gross Margin
61.3%
Profit Margin
-19.9%
Rev Growth
+24.0%
D/E Ratio
0.34
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 61.3% | 61.3% | 61.3% |
| Operating Margin | -14.9% | -14.8% | -16.2% |
| Profit Margin | -19.9% | -18.5% | -18.7% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 242.99M | 245.23M | 253.21M |
| Gross Profit | 148.98M | 150.36M | 155.25M |
| Operating Income | -36,180,449 | -36,336,959 | -40,979,803 |
| Net Income | -48,406,908 | -45,232,819 | -47,387,261 |
| Gross Margin | 61.3% | 61.3% | 61.3% |
| Operating Margin | -14.9% | -14.8% | -16.2% |
| Profit Margin | -19.9% | -18.5% | -18.7% |
| Rev Growth | +24.0% | +24.2% | +22.9% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 205.68M | 211.33M | 200.60M |
| Total Equity | 600.41M | 627.14M | 564.78M |
| D/E Ratio | 0.34 | 0.34 | 0.36 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -47,660,000 | -53,758,331 | -46,826,478 |
| Free Cash Flow | -27,352,313 | -27,764,891 | -38,614,891 |